Egyptian Liver Journal

Table 5 Relationship between baseline Lp-PLA2 and gender, smoking, hypertension, diabetes, and ease of treatment

From: The effect of hepatitis C virologic clearance on cardiovascular disease biomarker lipoprotein-associated phospholipase A2 and its relation to serum lipids

Parameter		Lp-PLA2 (ng/ml)	t-test or ANOVA
Parameter		Lp-PLA2 (ng/ml)	t or F	p
Gender	Male (n = 55)	358.018 ± 77.133	5.832	<0.001
Gender	Female (n = 35)	271.8 ± 51.467	5.832	<0.001
Smoking	Smoker (n = 18)	444.833 ± 26.425	10.83	<0.001
Smoking	Non-smoker (n = 72)	294.403 ± 57.237	10.83	<0.001
Hypertension	Hypertensive (n = 15)	396.8 ± 69.548	4.17	<0.001
Hypertension	Normotensive (n = 75)	310.027 ± 74.298	4.17	<0.001
Diabetes	Diabetic (n = 7)	398 ± 51.095	5.171	0.008†	D&P	0.440^‡
	Pre-diabetic (n = 13)	353.923 ± 86.238			D&N	0.015^‡
	Non-diabetic (n = 70)	311.671 ± 76.597			P&N	0.167^‡
Ease of treatment	Easy to treat (n = 45)	301.444 ± 78.506	−2.837	0.006
Ease of treatment	Difficult to treat (n = 45)	347.533 ± 75.582	−2.837	0.006

†ANOVA (F) test, ^‡post hoc test
Abbreviations: n, number; Lp-PLA2, lipoprotein-associated phospholipase A2; D, diabetic; P, pre-diabetic; N, non-diabetic

Back to article page